Programmed death ligand-1 immunohistochemistry-A new challenge for pathologists

A perspective from members of the pulmonary pathology society

Lynette M. Sholl, Dara L. Aisner, Timothy Craig Allen, Mary Beth Beasley, Alain C. Borczuk, Philip T. Cagle, Vera Capelozzi, Sanja Dacic, Lida Hariri, Keith M. Kerr, Sylvie Lantuejoul, Mari Mino-Kenudson, Kirtee Raparia, Natasha Rekhtman, Sinchita Roy-Chowdhuri, Eric Thunnissen, Ming Sound Tsao, Yasushi Yatabe

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

The binding of programmed death ligand-1 and ligand-2 (PD-L1 and PD-L2) to PD-1 blocks T-cell-mediated immune response to tumor. Antibodies that target programmed death receptor-1 (PD-1) will block the ligandreceptor interface, thereby allowing T cells to attack the tumor and increase antitumor immune response. In clinical trials, PD-1 inhibitors have been associated with an approximately 20% overall response rate in unselected patients with non-small cell lung cancer, with sustained tumor response in a subset of patients treated by these immune checkpoint inhibitors. Facing a proliferation of PD-L1 immunohistochemistry clones, staining platforms, and scoring criteria, the pathologist must decide on the feasibility of introducing a newly approved companion diagnostic assay that may require purchase not only of a specific antibody kit but of a particular staining platform. Given the likely reality that clinical practice may, in the near future, demand access to 4 different PD-L1 antibodies coupled with different immunohistochemistry platforms, laboratories will be challenged with deciding among this variety of testing methods, each with its own potential benefits. Another immediate challenge to PD-L1 testing in lung cancer patients is that of access to adequate tumor tissue, given that non-small cell lung cancer samples are often extremely limited in size. With PD-L1 testing it has become clear that the historically used US regulatory approach of one assay-one drug will not be sustainable. One evolving concept is that of complementary diagnostics, a novel regulatory pathway initiated by the US Food and Drug Administration, which is distinct from companion diagnostics in that it may present additional flexibility. Although pathologists need to face the practical reality that oncologists will be asking regularly for the PD-L1 immunohistochemistry status of their patients' tumors, we should also keep in mind that there may be room for improvement of biomarkers for immunotherapy response. The field is rich with opportunities for investigation into biomarkers of immunotherapy response, particularly in the form of collaborative, multidisciplinary studies that incorporate oncologists, pathologists, and basic scientists. Pathologists must take the lead in the rational incorporation of these biomarkers into clinical practice.

Original languageEnglish (US)
Pages (from-to)341-344
Number of pages4
JournalArchives of Pathology and Laboratory Medicine
Volume140
Issue number4
DOIs
StatePublished - Apr 1 2016

Fingerprint

Immunohistochemistry
Death Domain Receptors
Pathology
Ligands
Lung
Biomarkers
Neoplasms
Non-Small Cell Lung Carcinoma
Immunotherapy
Antibodies
Staining and Labeling
T-Lymphocytes
United States Food and Drug Administration
Lung Neoplasms
Clone Cells
Pathologists
Clinical Trials
Pharmaceutical Preparations
Oncologists

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medical Laboratory Technology

Cite this

Programmed death ligand-1 immunohistochemistry-A new challenge for pathologists : A perspective from members of the pulmonary pathology society. / Sholl, Lynette M.; Aisner, Dara L.; Allen, Timothy Craig; Beasley, Mary Beth; Borczuk, Alain C.; Cagle, Philip T.; Capelozzi, Vera; Dacic, Sanja; Hariri, Lida; Kerr, Keith M.; Lantuejoul, Sylvie; Mino-Kenudson, Mari; Raparia, Kirtee; Rekhtman, Natasha; Roy-Chowdhuri, Sinchita; Thunnissen, Eric; Tsao, Ming Sound; Yatabe, Yasushi.

In: Archives of Pathology and Laboratory Medicine, Vol. 140, No. 4, 01.04.2016, p. 341-344.

Research output: Contribution to journalArticle

Sholl, LM, Aisner, DL, Allen, TC, Beasley, MB, Borczuk, AC, Cagle, PT, Capelozzi, V, Dacic, S, Hariri, L, Kerr, KM, Lantuejoul, S, Mino-Kenudson, M, Raparia, K, Rekhtman, N, Roy-Chowdhuri, S, Thunnissen, E, Tsao, MS & Yatabe, Y 2016, 'Programmed death ligand-1 immunohistochemistry-A new challenge for pathologists: A perspective from members of the pulmonary pathology society', Archives of Pathology and Laboratory Medicine, vol. 140, no. 4, pp. 341-344. https://doi.org/10.5858/arpa.2015-0506-SA
Sholl, Lynette M. ; Aisner, Dara L. ; Allen, Timothy Craig ; Beasley, Mary Beth ; Borczuk, Alain C. ; Cagle, Philip T. ; Capelozzi, Vera ; Dacic, Sanja ; Hariri, Lida ; Kerr, Keith M. ; Lantuejoul, Sylvie ; Mino-Kenudson, Mari ; Raparia, Kirtee ; Rekhtman, Natasha ; Roy-Chowdhuri, Sinchita ; Thunnissen, Eric ; Tsao, Ming Sound ; Yatabe, Yasushi. / Programmed death ligand-1 immunohistochemistry-A new challenge for pathologists : A perspective from members of the pulmonary pathology society. In: Archives of Pathology and Laboratory Medicine. 2016 ; Vol. 140, No. 4. pp. 341-344.
@article{fde3e55950a94d319a8f793758f52173,
title = "Programmed death ligand-1 immunohistochemistry-A new challenge for pathologists: A perspective from members of the pulmonary pathology society",
abstract = "The binding of programmed death ligand-1 and ligand-2 (PD-L1 and PD-L2) to PD-1 blocks T-cell-mediated immune response to tumor. Antibodies that target programmed death receptor-1 (PD-1) will block the ligandreceptor interface, thereby allowing T cells to attack the tumor and increase antitumor immune response. In clinical trials, PD-1 inhibitors have been associated with an approximately 20{\%} overall response rate in unselected patients with non-small cell lung cancer, with sustained tumor response in a subset of patients treated by these immune checkpoint inhibitors. Facing a proliferation of PD-L1 immunohistochemistry clones, staining platforms, and scoring criteria, the pathologist must decide on the feasibility of introducing a newly approved companion diagnostic assay that may require purchase not only of a specific antibody kit but of a particular staining platform. Given the likely reality that clinical practice may, in the near future, demand access to 4 different PD-L1 antibodies coupled with different immunohistochemistry platforms, laboratories will be challenged with deciding among this variety of testing methods, each with its own potential benefits. Another immediate challenge to PD-L1 testing in lung cancer patients is that of access to adequate tumor tissue, given that non-small cell lung cancer samples are often extremely limited in size. With PD-L1 testing it has become clear that the historically used US regulatory approach of one assay-one drug will not be sustainable. One evolving concept is that of complementary diagnostics, a novel regulatory pathway initiated by the US Food and Drug Administration, which is distinct from companion diagnostics in that it may present additional flexibility. Although pathologists need to face the practical reality that oncologists will be asking regularly for the PD-L1 immunohistochemistry status of their patients' tumors, we should also keep in mind that there may be room for improvement of biomarkers for immunotherapy response. The field is rich with opportunities for investigation into biomarkers of immunotherapy response, particularly in the form of collaborative, multidisciplinary studies that incorporate oncologists, pathologists, and basic scientists. Pathologists must take the lead in the rational incorporation of these biomarkers into clinical practice.",
author = "Sholl, {Lynette M.} and Aisner, {Dara L.} and Allen, {Timothy Craig} and Beasley, {Mary Beth} and Borczuk, {Alain C.} and Cagle, {Philip T.} and Vera Capelozzi and Sanja Dacic and Lida Hariri and Kerr, {Keith M.} and Sylvie Lantuejoul and Mari Mino-Kenudson and Kirtee Raparia and Natasha Rekhtman and Sinchita Roy-Chowdhuri and Eric Thunnissen and Tsao, {Ming Sound} and Yasushi Yatabe",
year = "2016",
month = "4",
day = "1",
doi = "10.5858/arpa.2015-0506-SA",
language = "English (US)",
volume = "140",
pages = "341--344",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "4",

}

TY - JOUR

T1 - Programmed death ligand-1 immunohistochemistry-A new challenge for pathologists

T2 - A perspective from members of the pulmonary pathology society

AU - Sholl, Lynette M.

AU - Aisner, Dara L.

AU - Allen, Timothy Craig

AU - Beasley, Mary Beth

AU - Borczuk, Alain C.

AU - Cagle, Philip T.

AU - Capelozzi, Vera

AU - Dacic, Sanja

AU - Hariri, Lida

AU - Kerr, Keith M.

AU - Lantuejoul, Sylvie

AU - Mino-Kenudson, Mari

AU - Raparia, Kirtee

AU - Rekhtman, Natasha

AU - Roy-Chowdhuri, Sinchita

AU - Thunnissen, Eric

AU - Tsao, Ming Sound

AU - Yatabe, Yasushi

PY - 2016/4/1

Y1 - 2016/4/1

N2 - The binding of programmed death ligand-1 and ligand-2 (PD-L1 and PD-L2) to PD-1 blocks T-cell-mediated immune response to tumor. Antibodies that target programmed death receptor-1 (PD-1) will block the ligandreceptor interface, thereby allowing T cells to attack the tumor and increase antitumor immune response. In clinical trials, PD-1 inhibitors have been associated with an approximately 20% overall response rate in unselected patients with non-small cell lung cancer, with sustained tumor response in a subset of patients treated by these immune checkpoint inhibitors. Facing a proliferation of PD-L1 immunohistochemistry clones, staining platforms, and scoring criteria, the pathologist must decide on the feasibility of introducing a newly approved companion diagnostic assay that may require purchase not only of a specific antibody kit but of a particular staining platform. Given the likely reality that clinical practice may, in the near future, demand access to 4 different PD-L1 antibodies coupled with different immunohistochemistry platforms, laboratories will be challenged with deciding among this variety of testing methods, each with its own potential benefits. Another immediate challenge to PD-L1 testing in lung cancer patients is that of access to adequate tumor tissue, given that non-small cell lung cancer samples are often extremely limited in size. With PD-L1 testing it has become clear that the historically used US regulatory approach of one assay-one drug will not be sustainable. One evolving concept is that of complementary diagnostics, a novel regulatory pathway initiated by the US Food and Drug Administration, which is distinct from companion diagnostics in that it may present additional flexibility. Although pathologists need to face the practical reality that oncologists will be asking regularly for the PD-L1 immunohistochemistry status of their patients' tumors, we should also keep in mind that there may be room for improvement of biomarkers for immunotherapy response. The field is rich with opportunities for investigation into biomarkers of immunotherapy response, particularly in the form of collaborative, multidisciplinary studies that incorporate oncologists, pathologists, and basic scientists. Pathologists must take the lead in the rational incorporation of these biomarkers into clinical practice.

AB - The binding of programmed death ligand-1 and ligand-2 (PD-L1 and PD-L2) to PD-1 blocks T-cell-mediated immune response to tumor. Antibodies that target programmed death receptor-1 (PD-1) will block the ligandreceptor interface, thereby allowing T cells to attack the tumor and increase antitumor immune response. In clinical trials, PD-1 inhibitors have been associated with an approximately 20% overall response rate in unselected patients with non-small cell lung cancer, with sustained tumor response in a subset of patients treated by these immune checkpoint inhibitors. Facing a proliferation of PD-L1 immunohistochemistry clones, staining platforms, and scoring criteria, the pathologist must decide on the feasibility of introducing a newly approved companion diagnostic assay that may require purchase not only of a specific antibody kit but of a particular staining platform. Given the likely reality that clinical practice may, in the near future, demand access to 4 different PD-L1 antibodies coupled with different immunohistochemistry platforms, laboratories will be challenged with deciding among this variety of testing methods, each with its own potential benefits. Another immediate challenge to PD-L1 testing in lung cancer patients is that of access to adequate tumor tissue, given that non-small cell lung cancer samples are often extremely limited in size. With PD-L1 testing it has become clear that the historically used US regulatory approach of one assay-one drug will not be sustainable. One evolving concept is that of complementary diagnostics, a novel regulatory pathway initiated by the US Food and Drug Administration, which is distinct from companion diagnostics in that it may present additional flexibility. Although pathologists need to face the practical reality that oncologists will be asking regularly for the PD-L1 immunohistochemistry status of their patients' tumors, we should also keep in mind that there may be room for improvement of biomarkers for immunotherapy response. The field is rich with opportunities for investigation into biomarkers of immunotherapy response, particularly in the form of collaborative, multidisciplinary studies that incorporate oncologists, pathologists, and basic scientists. Pathologists must take the lead in the rational incorporation of these biomarkers into clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=84964039838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964039838&partnerID=8YFLogxK

U2 - 10.5858/arpa.2015-0506-SA

DO - 10.5858/arpa.2015-0506-SA

M3 - Article

VL - 140

SP - 341

EP - 344

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 4

ER -